We sit down with Dr. CJ Barnum, Director of Neuroscience at Inmune Bio, Inc. to talk about the recently announced grant from the NIH for $2.9 million to test a new hypothesis that #neuroinflammation plays a major role in treatment resistant depression (TRD).
This money will support a first-of-its-kind phase 2 study that will be conducted at two sites in the U.S. – Emory University School of Medicine in Atlanta and University of Alabama in Birmingham. Patient enrollment will be based on levels of inflammatory biomarkers and anhedonia, rather than being an all-comers study which is the standard in today’s psychology trials.
We also discuss INmune Bio Inc.’s developing novel therapies targeting distinct parts of the patient’s immune system to fight disease. This includes drug candidates to treat #cancer, and #Alzheimers disease.
To find out more about Inmune Bio Inc. you can check out there website: